Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar appeared on CW39's H-Town Live to discuss the company's innovative approach to breast cancer prevention. The segment highlighted Anixa's collaboration with the Cleveland Clinic in developing a novel vaccine targeting triple-negative breast cancer (TNBC), the most aggressive form of the disease.

The vaccine, currently in clinical trials, is designed to target a specific protein present in TNBC cells but absent in normal breast tissue. The goal is to stimulate the immune system to eliminate cancer cells before they develop into tumors, potentially eliminating the need for traditional treatments like chemotherapy and surgery.

Anixa Biosciences (NASDAQ: ANIX) reported significant progress in 2024, maintaining strong financials with $20 million in cash and investments after using only $7 million during the fiscal year. The company presented positive preliminary Phase 1 data for their breast cancer vaccine at SITC, showing protocol-defined immune responses in over 70% of patients across three groups: recurrence, prevention, and therapeutic.

Their CAR-T program for ovarian cancer progressed through the second dose cohort and began the third, with one patient from the first cohort showing strong response and surviving 21+ months post-treatment. The company expanded their vaccine development to include prostate, lung, and colon cancers.

For 2025, Anixa plans to complete the breast cancer vaccine Phase 1 trial and initiate Phase 2, complete treatment of third through fifth dose cohorts in the CAR-T trial, and continue developing vaccines for multiple cancer types. With a 2.5-year cash runway and debt-free structure, the company is positioned to execute its development plans.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the iAccess Alpha Virtual Best Ideas Winter Conference 2024. The event will take place on December 10th and 11th, 2024.

Dr. Amit Kumar, CEO of Anixa, will deliver a presentation on Tuesday, December 10th at 2:00 p.m. EST. The company's management team will be available for one-on-one meetings with qualified investors on Wednesday, December 11th.

The conference, hosted by iAccess Alpha, features companies recommended by an investor network and follows a two-day format with company webcasts on the first day and one-on-one management meetings on the second day.

Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. The decision to invest in Bitcoin is presented as part of their financial management strategy, with the company citing Bitcoin's growing recognition as a mainstream asset class, inflation-resistant qualities, and the recent approval of Bitcoin ETFs as supporting factors.

Anixa Biosciences (NASDAQ: ANIX) has initiated dosing in the third cohort of its Phase 1 ovarian cancer CAR-T clinical trial, conducted in partnership with Moffitt Cancer Center. The new cohort receives one million CAR-positive cells, a tenfold increase from the initial dose. No dose-limiting toxicity was observed in the first two cohorts. The trial targets the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer who have progressed on at least two prior therapies. Notably, one patient from the first cohort showed unusual stability and mild improvement for over a year post-infusion, with tumor biopsy revealing necrosis and T cell infiltration.

Anixa Biosciences and Cleveland Clinic presented updated positive data from their Phase 1 breast cancer vaccine trial at the SITC Annual Meeting. The vaccine, targeting α-lactalbumin protein, showed safety and tolerability across all three cohorts, with over 70% of patients exhibiting protocol-defined immune responses. The trial includes patients who completed triple-negative breast cancer treatment, high-risk individuals with genetic mutations, and patients receiving Keytruda. The primary side effect was injection site irritation. Based on these positive results, a Phase 2 study is planned for 2025, focusing on newly diagnosed breast cancer patients in the neoadjuvant setting.

Anixa Biosciences (NASDAQ: ANIX) announced that additional data from the Phase 1 clinical trial of its breast cancer vaccine will be made public on November 8, 2024, at 12:15pm CT. The presentation, titled 'Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC,' will be presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data will be available on the company's website, accompanied by a press release analyzing the results.

Anixa Biosciences (NASDAQ: ANIX) announced its upcoming presentation at the Sidoti Micro-Cap Virtual Conference on November 14, 2024, at 1:00pm ET. Chairman and CEO Dr. Amit Kumar will present company updates and clinical program developments. The presentation follows the release of latest breast cancer clinical trial data scheduled for November 8, 2024.

Dr. Kumar will also provide updates on their CAR-T trial for recurrent and resistant ovarian cancer patients. Both trials are reportedly producing positive results that exceed expectations. The conference offers 1x1 meetings open to all registered investors.

Anixa Biosciences (NASDAQ: ANIX) announced that additional data from its Phase 1 breast cancer vaccine clinical trial will be presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 6-10, 2024. The presentation, titled 'Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC,' will be delivered by Dr. Emily Rhoades from Cleveland Clinic. The trial is being conducted in collaboration with Cleveland Clinic and funded by the U.S. Department of Defense.